Table 1.
Characteristics of included studies.
| Included trials | Sample size (T/C) | Age (T/C) | Cancer stage | Intervention (T/C)a | Treatment course (C/W/D) | KPS | ||
|---|---|---|---|---|---|---|---|---|
| Gu et al., 2012 | 46 | 48 | 51.7 | 58.4 | - | FEJ + TCF, DC, FOLFOX4, DCF | 1 C, 4 W/C | >60 |
| Nan and Yang, 2007 | 130 | 86 | 18–75 | III-IV | BJD + MFV | 1 C, 6 W/C | ≥60 | |
| Zhang et al., 2010 | 30 | 30 | 45.2 ± 12.1 | 46.3 ± 11.8 | - | BJD + PTX, OXA, CF, 5-FU | 2–4 C, 14 D/C | - |
| Li, 2008 | 16 | 16 | 53.2 | 53.6 | - | JBD + TF | 2 C, 3 W/C | ≥70 |
| G. Q. Zhao and J. Z. Zhao, 2008 | 38 | 32 | 59.1 ± 9.4 | 57.8 ± 8.2 | I–III | JBD + MFP | 4 C, 28 D/C | - |
| Le et al., 2015 | 45 | 45 | 62.5 ± 5.5 | 61.7 ± 5.8 | II–IV | JBD + FOLFOX4 | 4 C, 14 D/C | ≥60 |
| Zhang et al., 2012 | 46 | 46 | 45.35 ± 6.7 | 48.35 ± 7.2 | I–IV | JBD + PTX, CF, 5-FU | 4 C, 2 W/C | ≥60 |
| Zhang et al., 2016 | 30 | 30 | 48.52 ± 4.58 | 45.52 ± 5.58 | II-III | JBD + FOLFOX4 | 6 C, 1 W/C | - |
| Du et al., 2011 | 120 | 120 | 55.2 | IV | JBD + FOLFOX4 | 2 C, 21 D/C | ≥60 | |
| Wang and Liu, 2015 | 30 | 30 | 70.2 ± 2.3 | 72.6 ± 2.1 | III-IV | JBD + EPI, DDP, CAP | 4 C, 10 D/C | ≥60 |
| Zheng et al., 2012 | 35 | 30 | 64 | 63 | IIIB-IV | JBD + L-OHP, 5-FU/CF | 2 C, 21 D/C | ≥60 |
| Guo et al., 2015 | 121 | 118 | 73.1 ± 4.4 | 74.1 ± 4.0 | III-IV | JBD + XELOX | 6 C, 3 W/C | ≥60 |
| Huang et al., 2010 | 20 | 20 | 46.7 ± 11.9 | 45.3 ± 12.5 | - | JBD + 5-FU, CF, DDP/PTX | 2–4 C, 2 W/C | - |
| Mo and Xiao, 2008 | 32 | 32 | 47.5 ± 8.6 | 48.3 ± 7.9 | I–IV | JBD + FLP | 4 C, 28 D/C | >60 |
| Lin and Wu, 2007 | 30 | 20 | 24~65 | - | JBD + PTX, CF, FU | 4 C, 2 W/C | - | |
| Tian and Han, 2011 | 42 | 39 | 56.83 ± 8.74 | 55.72 ± 7.32 | - | JBD + DOC, DDP | 2 C, 21 D/C | ≥60 |
| Lai et al., 2010 | 25 | 30 | 44 | 48 | - | JBD + TAX, 5-FU, CF | 4 C, 10 D/C | ≥50 |
| Huang and Xu, 2015 | 45 | 45 | 62.5 ± 5.5 | 61.7 ± 5.8 | - | JBD + tegafur | 1 C, 4 W/C | ≥60 |
| Sun et al., 2009 | 414 | 255 | - | - | JBD + CTX | 6 C, 4 W/C | - | |
| Bu et al., 2013 | 30 | 30 | 48 | 49 | III A-IV | FEJ + XELOX | 3 C, 3 W/C | ≥60 |
| Cui et al., 2015 | 30 | 30 | 61 | 57.5 | - | JBD + TAX, DDP | 6 C, 3 W/C | - |
| Zhao and Zhang, 2012 | 38 | 32 | 69.7 | 71.3 | III-IV | JBD + L-OHP, 5-FU | 3 C, 2 W/C | >50 |
| Ning et al., 1985 | 180 | 146 | 51 | III-IV | JBD + MMC, 5-FU, VCR | 1 C, 6 W/C | - | |
| Wang et al., 2016 | 40 | 38 | 32–75 | 35–73 | II-IIIA | JBD + FOLFOX4 | 12 C, 4 W/C | ≥80 |
| Liu, 2010 | 69 | 34 | 25–84 | 32–82 | II-III | JBD + FOLFOX4 | 6–8 C, 2 W/C | >60 |
| Chen and Wang, 1996 | 40 | 20 | 58 | 60 | II-III | JBD + 5-FU, MMC, ADM | 1 C, 6 W/C | - |
Note. T/C: treatment group/control group; C: cycle; W: week; D: day; KPS: Karnofsky; FEJ: Compound E Jiao Jiang; TCF: PTX (paclitaxel) and DDP (cisplatin) and 5-Fu (5-fluorouracil); DC: DOC (docetaxel) and DDP; FOLFOX4: OXA (oxaliplatin) and CF (calcium folinate) and 5-Fu; DCF: DOC and DDP and 5-Fu; BJOL: bushenjianpi oral liquid; MFV: MMC (mitomycin) and 5-Fu and VCR (vincristine); BJD: bushenjianpi decoction; JBD: Jianpi Bushen decoction; TF: PTX and 5-Fu; MFP: 5-Fu and MMC and DDP and CF; EPI: pirarubicin; CAP: capecitabine; L-OHP: oxaliplatin; XELOX: OXA and CAP; FLP: CF and 5-Fu and DDP; FU: fluorouracil; CTX: cytoxan; TAX: paclitaxel; VCR: leurocristine; ADM: doxorubicin. aThe treatment group was given JPBS Chinese medicine combined with chemotherapy, and the control group was given only chemotherapy.